JP2005502643A5 - - Google Patents

Download PDF

Info

Publication number
JP2005502643A5
JP2005502643A5 JP2003518549A JP2003518549A JP2005502643A5 JP 2005502643 A5 JP2005502643 A5 JP 2005502643A5 JP 2003518549 A JP2003518549 A JP 2003518549A JP 2003518549 A JP2003518549 A JP 2003518549A JP 2005502643 A5 JP2005502643 A5 JP 2005502643A5
Authority
JP
Japan
Prior art keywords
compound
leukemia
tyrosine kinase
kinase activity
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2003518549A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005502643A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2002/008941 external-priority patent/WO2003013540A1/en
Publication of JP2005502643A publication Critical patent/JP2005502643A/ja
Publication of JP2005502643A5 publication Critical patent/JP2005502643A5/ja
Withdrawn legal-status Critical Current

Links

JP2003518549A 2001-08-10 2002-08-09 白血病処置のための単独またはｓｔｉ５７１と組み合せたｃ−ｓｒｃインヒビターの使用 Withdrawn JP2005502643A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31169001P 2001-08-10 2001-08-10
PCT/EP2002/008941 WO2003013540A1 (en) 2001-08-10 2002-08-09 Use of c-src inhibitors alone or in combination with sti571 for the treatment of leukaemia

Publications (2)

Publication Number Publication Date
JP2005502643A JP2005502643A (ja) 2005-01-27
JP2005502643A5 true JP2005502643A5 (https=) 2006-01-05

Family

ID=23208019

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003518549A Withdrawn JP2005502643A (ja) 2001-08-10 2002-08-09 白血病処置のための単独またはｓｔｉ５７１と組み合せたｃ−ｓｒｃインヒビターの使用

Country Status (6)

Country Link
US (5) US20040248906A1 (https=)
EP (2) EP2258371A1 (https=)
JP (1) JP2005502643A (https=)
CN (1) CN1523991A (https=)
CA (2) CA2450777C (https=)
WO (1) WO2003013540A1 (https=)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
CA2466762A1 (en) * 2001-12-04 2003-06-12 Onyx Pharmaceuticals, Inc. Raf-mek-erk pathway inhibitors to treat cancer
CL2003002287A1 (es) 2002-11-25 2005-01-14 Wyeth Corp COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS
US7276519B2 (en) 2002-11-25 2007-10-02 Wyeth Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors
US20050009891A1 (en) 2003-07-09 2005-01-13 Lee Francis Y. Combination of SRC Kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases
US20050192314A1 (en) 2003-11-13 2005-09-01 Ambit Biosciences Corporation Urea derivatives as C-kit modulators
WO2005063720A1 (ja) * 2003-12-25 2005-07-14 Nippon Shinyaku Co., Ltd. アミド誘導体及び医薬
EP1713806B1 (en) * 2004-02-14 2013-05-08 Irm Llc Compounds and compositions as protein kinase inhibitors
EP2298291A3 (en) 2004-06-18 2011-08-03 Agennix USA Inc. Kinase inhibitors for treating cancers
RU2007123675A (ru) * 2004-11-24 2008-12-27 Новартис АГ (CH) Комбинации ингибиторов jak
US20090099197A1 (en) * 2005-11-15 2009-04-16 Bristol-Myers Squibb Company Methods of Identifying and Treating Individuals Exhibiting MDR-1 Overexpression With Protein Tyrosine Kinase Inhibitors and Combinations Thereof
WO2007109527A1 (en) * 2006-03-17 2007-09-27 Bristol-Myers Squibb Company Methods of identifying and treating individuals exhibiting mutant bcr/abl kinase polypeptides
CN101415426A (zh) * 2006-04-07 2009-04-22 诺瓦提斯公司 c-Src抑制剂与嘧啶基氨基苯甲酰胺类化合物的组合治疗白血病的用途
BRPI0622054B8 (pt) 2006-09-22 2021-05-25 Oxford Amherst Llc composto e composição farmacêutica
WO2008077064A2 (en) * 2006-12-19 2008-06-26 Board Of Regents, The University Of Texas System Biomarker identifying the reactivation of stat3 after src inhibition
IL295053A (en) * 2007-03-28 2022-09-01 Pharmacyclics Llc Broton tyrosine kinase inhibitors
US20120101114A1 (en) 2007-03-28 2012-04-26 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
US20100331297A1 (en) * 2007-11-07 2010-12-30 Foldrx Pharmaceuticals, Inc. Modulation of protein trafficking
ES2660418T3 (es) 2008-07-16 2018-03-22 Pharmacyclics Llc Inhibidores de la tirosina quinasa de Bruton para el tratamiento de tumores sólidos
CN107898791A (zh) 2010-06-03 2018-04-13 药品循环有限责任公司 布鲁顿酪氨酸激酶(btk)抑制剂的应用
US9138436B2 (en) 2011-07-13 2015-09-22 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
AU2013250726B2 (en) * 2012-04-20 2017-01-05 Advinus Therapeutics Limited Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof
KR20190043648A (ko) * 2012-05-31 2019-04-26 파마사이언스 인크. 단백질 키나제 저해제
JO3754B1 (ar) 2012-06-04 2021-01-31 Pharmacyclics Llc أشكال كريستالين لمثبط أنزيم كيناز تيروسين بروتون
CN104704129A (zh) 2012-07-24 2015-06-10 药品循环公司 与对布鲁顿酪氨酸激酶(btk)抑制剂的抗性相关的突变
EA201590855A1 (ru) 2012-11-15 2015-11-30 Фармасайкликс, Инк. Соединения пирролопиримидина как ингибиторы киназ
US10144828B2 (en) 2012-11-21 2018-12-04 Stratasys, Inc. Semi-crystalline build materials
CA2919996A1 (en) 2013-08-02 2015-02-05 Pharmacyclics Llc Methods for the treatment of solid tumors
US9415050B2 (en) 2013-08-12 2016-08-16 Pharmacyclics Llc Methods for the treatment of HER2 amplified cancer
CA2925124A1 (en) 2013-09-30 2015-04-02 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
WO2015143400A1 (en) 2014-03-20 2015-09-24 Pharmacyclics, Inc. Phospholipase c gamma 2 and resistance associated mutations
US20170114323A1 (en) 2014-06-19 2017-04-27 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency
AU2015296215A1 (en) 2014-08-01 2017-03-23 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
SG11201700849XA (en) 2014-08-07 2017-03-30 Pharmacyclics Llc Novel formulations of a bruton's tyrosine kinase inhibitor
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
CN108101905A (zh) * 2016-11-24 2018-06-01 中国科学院上海药物研究所 嘧啶并[5,4-b]吲嗪或嘧啶并[5,4-b]吡呤化合物、其制备方法及用途
US20210369635A1 (en) 2017-11-29 2021-12-02 Adaptive Phage Therapeutics, Inc. Novel methods of vaccination using icosahedral phage
RS66727B1 (sr) 2018-09-10 2025-05-30 Mirati Therapeutics Inc Kombinacija dasatiniba i adagrasiba za primenu u lečenju nesitnoćelijskog kancera pluća
US12233177B2 (en) 2019-09-16 2025-02-25 Amgen Inc. Method for external sterilization of drug delivery device
AR122159A1 (es) * 2020-05-28 2022-08-17 Novartis Ag Inhibidores de mll1 y agentes antineoplásicos
WO2021252450A1 (en) 2020-06-08 2021-12-16 Adaptive Phage Therapeutics, Inc. Phage display vaccine for covid-19 using a novel peptide sequence
US12371667B2 (en) 2021-05-13 2025-07-29 Washington University Enhanced methods for inducing and maintaining naive human pluripotent stem cells

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0682027B1 (de) * 1994-05-03 1997-10-15 Novartis AG Pyrrolopyrimidinderivate mit antiproliferativer Wirkung
JP4145955B2 (ja) 1994-09-29 2008-09-03 ノバルティス アクチェンゲゼルシャフト ピロロ〔２，３−ｄ〕ピリミジン及びその使用
GB9516842D0 (en) 1995-08-17 1995-10-18 Ciba Geigy Ag Various acylated oligopeptides
GB9517060D0 (en) 1995-08-17 1995-10-25 Ciba Geigy Ag Acylated oligopeptide derivatives
BR9611157A (pt) * 1995-11-01 1999-03-30 Novartis Ag Derivados de purina e processos para sua preparação
CH690773A5 (de) 1996-02-01 2001-01-15 Novartis Ag Pyrrolo(2,3-d)pyrimide und ihre Verwendung.
AU1794697A (en) 1996-03-06 1997-09-22 Novartis Ag 7-alkyl-pyrrolo{2,3-d}pyrimidines
AU3176297A (en) 1996-06-25 1998-01-14 Novartis Ag Substituted 7-amino-pyrrolo{3,2-d}pyrimidines and the use thereof
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
US6100254A (en) * 1997-10-10 2000-08-08 Board Of Regents, The University Of Texas System Inhibitors of protein tyrosine kinases
PL215901B1 (pl) 1999-04-15 2014-02-28 Bristol Myers Squibb Co Cykliczny inhibitor bialkowych kinaz tyrozynowych, jego zastosowanie oraz kompozycja farmaceutyczna zawierajaca taki zwiazek
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
US20050215795A1 (en) 2004-02-06 2005-09-29 Bang-Chi Chen Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
TWI338004B (en) 2004-02-06 2011-03-01 Bristol Myers Squibb Co Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors

Similar Documents

Publication Publication Date Title
JP2005502643A5 (https=)
JP2009532438A5 (https=)
JP2024133474A5 (https=)
JP2004531549A5 (https=)
RU2003114752A (ru) Лечение желудочно-кишечных стромальных опухолей
US9161946B2 (en) Dosing methods for treating disease
JP2017529382A5 (https=)
JP2019517587A5 (https=)
JP6792269B2 (ja) 夜間胃酸過分泌に対するベンズイミダゾール誘導体の使用
JP2006514092A5 (https=)
RU2012147511A (ru) Применение ингибиторов c-src в комбинации с пиримидиламинобензамидом для лечения лейкоза
JP2009511450A5 (https=)
JP2020529995A (ja) 行動の変化の治療方法
BG108339A (bg) Лечение на деменция и дегенеративни разстройства с междинни дози lhrh-антагонисти
JP2004527493A (ja) シグナル変換阻害剤とエポチロン誘導体とを含有してなる組合せ剤
JP2021522246A (ja) 癌治療のための併用
TR201806682T4 (tr) Farmasötik kombinasyonlar.
TWI841027B (zh) 手部溼疹之治療
TW201834649A (zh) 癌症療法
JP2019530711A5 (https=)
JP2006505582A5 (https=)
RU2006125741A (ru) Комбинация (а) n-{5-[4-(4-метилпиперазинометил)бензоиламило]-2-метилфенил}-4-(3-пиридил)-2-пиримидинамина и (б) по меньшей мере одного ингибитора гипузинации и ее применение
JP2007514699A5 (https=)
CA2504665A1 (en) Combination of a nitrogen mustard analogue and imatinib for the treatment of chronic lymphocytic leukemia
US20080234285A1 (en) Combination of Organic Compounds